Magic mushroom compound tested for Tough-to-Treat OCD
NCT ID NCT04882839
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a drug called psilocybin, given alongside talk therapy, can help people with severe obsessive-compulsive disorder (OCD) who haven't gotten better with standard treatments. Fifteen adults will receive three eight-hour sessions under the influence of psilocybin, plus 12 therapy sessions. Researchers will measure changes in OCD symptoms, anxiety, and depression to see if the approach is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- psilocybin
- What this could lead to
- If it works, this could point toward a new treatment option for people with severe OCD who haven't been helped by standard therapies.
- What could go wrong
- This is a very small early-phase trial with only 15 people, so results may not apply to everyone. Psilocybin can cause intense psychological experiences and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2024
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. DSM-5 diagnosis of OCD established by a trained clinician interview and confirmed by Mini International Neuropsychiatric Interview MINI (edition 7). 2\. Y-BOCS score of 16 or greater at evaluation 3. Treatment resistant- Patients; must have failed at least one medication and/or therapy trial of standard care treatment for OCD. 4\. Age: 18 Years to 65 Years 5. Has been off selective serotonin inhibitors for five half-lives of the drug plus 2 weeks. 6\. Must avoid starting new psychotherapy or psychiatric (medical) treatment during the study, without consulting the study team. 7\. Are willing to refrain from taking any psychiatric medications or recreational drugs during the study period. 8\. Must have a negative pregnancy test at study entry and prior to each experiential/ psychedelic session, if able to bear children, and must agree to use adequate birth control. 9\. Must be willing to sign a medical release form for the investigators to communicate directly with their therapist and doctors to confirm a medication and/or medical history. This is decided on a case by case basis upon the discretion of the PI. 10\. Must provide a contact (relative, spouse, close friend, or other caregiver) who is willing and able to be reached by the Clinical Investigators in the event of a participant becoming suicidal or any another relevant reason. 11\. Are willing to commit to medication dosing, experiential/ psychedelic sessions, psychotherapy and follow-up sessions and to complete the full evaluation. Exclusion Criteria: * 1\. Personal or immediate family history of schizophrenia, bipolar affective disorder, delusion disorder, paranoid disorder, or schizoaffective disorder. 2\. Current (or last 12-month) substance abuse disorder. 3. Unstable neurological or medical condition. 4. Active suicidal intent or last 12-month suicidal attempt. 5. A history of violence, self-harm, or harm to another. 6. Any unstable medical condition that may render study procedures unsafe. 7. Positive urine pregnancy test at the time of screening. 8. Any use of psychedelic drugs within the prior 12 months. 9. Lack of ability to sign Informed consent. Exclusion Criteria during the study 1. Any unusual reaction to any of the study procedures. 2. A participant's request to stop his/ her participation in the study. 3. Positive pregnancy test at any stage prior to the last psychedelic session
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obsessive compulsive disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beer Sheva Mental Health Center
RECRUITINGBeersheba, 8461144, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Brain scans and biosamples: mapping why OCD looks so different in every person
- Can a gentle electrical current quiet Obsessive-Compulsive symptoms?
- Can magnetic pulses ease OCD in teens who Haven't improved?
- Can a focused electric field quiet the Brain's obsessive signals?
- Can tailored brain stimulation quiet anxiety that drugs Can't?